ArticleBlood advances2025
Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractWith an aging population, multiple myeloma (MM) increasingly affects octogenarians (Octos; age of ≥80 years), yet data on their management and outcomes, particularly if treated outside clinical trials, remain limited. This retrospective study analyzed 652 patients aged ≥70 years, diagnosed with active MM between 2014 and 2023, identified in the Maccabi Healthcare Services medical records. Patient characteristics, treatment, time to next treatment (TTNT), overall survival (OS), and factors influencing outcomes, were compared between Octo and older adults (OL) aged 70 to <80 years. Octo patients (median age, 83 years) had more comorbidities and higher Charlson Comorbidity Index (CCI) scores than OL patients (≥6; 53% vs 23%), leading to lower rates of anti-MM therapy administration and reduced triplet/quadruplet regimen use. Over a median follow-up of 25 months, Octo patients had significantly shorter median OS; 25.9 vs 71.3 months, and 33 vs 76.9 months among treated patients only. TTNT was similar (17.8 vs 22.1 months). Multivariate analysis showed that triplet/quadruplet regimen was associated with improved TTNT (hazard ratio [HR], 0.61; P < .001) and OS (HR, 0.63; P < .001) compared with doublets, whereas higher CCI scores and age of ≥80 years predicted worse OS (HR, 1.5; P = .003; and HR, 2.27; P < .001; respectively). Daratumumab-based therapies enhanced TTNT in both age groups (HR, 0.54; P = .017). In conclusion, higher comorbidities in Octo patients adversely affected their management and survival. However, daratumumab positively influenced outcomes, underscoring the need for tailored approaches to optimize treatment in older patients with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.